March 30, 2023
Today, the U.S. Food and Drug Administration approved Tauramox, the first generic moxidectin injectable solution indicated for beef and nonlactating dairy cattle for the treatment and control of internal and external parasites in cattle.
Tauramox is an antiparasitic drug that contains the same concentration of moxidectin in the same injectable dosage form as the approved brand name drug product, Cydectin, which was first approved on May 20, 2005. As with Cydectin, residues in food products derived from beef and nonlactating dairy cattle treated with Tauramox will not represent a public health concern when the product is used according to the label.
Tauramox is available over the counter and is supplied in a 10 mg/ml concentration in 250 and 500 mL bottles.
The recommended rate of administration for Tauramox Injectable is 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight. People administering Tauramox should be careful to estimate the animal’s body weight as closely as possible or weigh animals individually. It is important to avoid overdosing or underdosing the animal to ensure each animal receives a complete dose based on a current body weight. Underdosing may result in ineffective treatment and encourage the development of parasite resistance.
Tauramox is sponsored by Norbrook Laboratories, Ltd., based in the United Kingdom.
For more information:
Issued by FDA Center for Veterinary Medicine.
For questions, Contact CVM.